January 24, 2023
An investigational new drug application for IMPT-314 has been cleared by the FDA. A phase 1/2 trial investigating the agent will be initiated in early 2023.
January 24, 2023
Cyrus M. Khan, MD, discusses the mechanism of action of glofitamab and its potential use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.
January 16, 2023
In an interview with Targeted Oncology, Ariel Perez, MD, explained the outcomes of patients with R/R large B-cell lymphoma who were treated with Pola-BR in the real-world setting, and the key takeaways from a single-institution study.
January 13, 2023
In an interview with Targeted Oncology, Yazan Samhouri, MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from ASH 2022.
January 10, 2023
In an interview with Targeted Oncology, Gustavo Fonseca, MD, FACP, discussed the positive health-related quality of life findings in patients with diffuse large B-cell lymphoma from the POLARIX study.
January 06, 2023
Based on data from a phase 1/2 study, a biologics license application has been accepted for glofitimab and the product has been granted priority review to for relapsed/refractory large B-cell lymphoma.
January 06, 2023
In an interview with Targeted Oncology, Cyrus M. Khan, MD, further discussed the background of the phase 1/2 trial and the potential use of glofitamab for patients with large B-cell lymphoma in the future.
January 05, 2023
In the diffuse large B-cell lymphoma and follicular lymphoma cohorts of the ELM-1 and ELM-2 trials, odronextamab led to high overall response rates.
December 16, 2022
Tisagenlecleucel led to durable efficacy and safety in the real-world setting for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
December 13, 2022
An extended progression-free survival and 54% reduction in the risk of death was shown with high-dose chemotherapy autologous stem cell transplantation consolidation therapy vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.